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Abstract 
Introduction: Long-term poor metabolic control promotes the occurrence of microvascular complications, such as cardiovascular autonomic 
neuropathy (CAN) and atherogenic hyperlipidaemia, which translates into increased mortality in patients with type 1 diabetes mellitus 
(T1DM). The aim of the study was to assess the prevalence of CAN in patients with T1DM in relation to treatment method (continuous 
subcutaneous insulin infusion, CSII, versus multiple daily injections using pens, MDI) and metabolic control.
Material and methods: The study group comprised 93 adults (60 women, 33 men), mean age 31 years, with T1DM being treated at a lo-
cal clinical centre from 2011 to 2015. The presence of CAN, the results of laboratory tests, and anthropometric data were analysed. The 
subjects were divided into two groups according to treatment method (CSII, MDI).
Results: The median duration of diabetes was 16 years. 61% of the subjects used MDI and 39% used CSII. 41% of the subjects presented 
with CAN (confirmed with the Ewing test using ProSciCard apparatus), with a significantly lower prevalence in the group of patients 
treated with CSII (15.4% vs. 60.4%; p < 0.001). The mean HbA1c level in the CSII-treated group was noticeably lower (7.44 ± 1.67% vs. 
8.55 ± 1.1%, p < 0.001), and these patients also had lower triglyceride levels (0.71 vs. 1.32 mmol/L, p < 0.001). Regardless of the treatment 
method, 72% of all patients under 40 years of age achieved their therapeutic target of LDL cholesterol level < 2.6 mmol/L, whereas only 
13% of all those over 40 years old achieved an LDL cholesterol level < 1.8 mmol/L.
Conclusions: The presented results draw attention to the high prevalence of CAN among T1DM patients. The study reveals the need 
for more intensive monitoring and treatment of hyperlipidaemia, despite good glycaemic control, especially in those over the age of 40 
years. (Endokrynol Pol 2019; 70 (4): 323–329)
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Introduction
Patients with type 1 diabetes mellitus (T1DM) are at 
greatest risk of chronic complications of diabetes, due 
to total insulin dependence from the beginning of the 
disease and its long-term duration [1]. However, most of 
the research and interest of clinicians concerns chronic 
complications in patients with type 2 DM. The number 
of cardiovascular and neurological complications of DM, 
including diabetic neuropathy, gradually increases with 
time [2]. The Diabetes Control and Complications Trial 
(DCCT) confirmed a gradual increase in the incidence 
of neuropathy, almost up to 40%, in patients with T1DM 
over the duration of the underlying disease [3]. In the 
EURODIAB study, 28% of T1DM patients had somatic 
peripheral neuropathy, and the features of diabetic au-
tonomic neuropathy presented in 36% of the subjects 
[4]. A low level of metabolic control and, most of all, 
the occurrence of hypo- and hyperglycaemic episodes, 
inducing oxidative stress and the activation of immu-
no-inflammatory processes, lead to the development 
and progression of life-threatening DM complications [5].
Cardiovascular autonomic neuropathy (CAN) 
manifests itself through reduced variability of the heart 
rhythm or orthostatic hypotension. It impairs the ability 
of the cardiovascular system to respond adequately to 
external stimuli, which significantly worsens patients’ 
quality of life. It has been shown that subclinical CAN 
may increase the mortality of patients [6]. It is associated 
with an increase in the frequency of ventricular arrhyth-
mia, one of the main mechanisms in the occurrence of 
sudden cardiac death in DM patients [6]. Additionally, 
there is an increased risk of death among the DM popu-
lation, despite improvements in glycaemic control. It 
has been found that patients with well-controlled T1DM 
(HbA1c ≤ 6.9%) have a two-fold increased risk of death 
from all causes, including cardiovascular complications, 
compared to the control group [7]. 
In order to optimise the evaluation of CAN, the Ew-
ing test is commonly used. It assesses the function of 
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(confirmed with a positive anti-GAD antibody test), whose age at 
the onset of the disease was < 40 years and in whom the duration 
of the disease exceeded five years. The exclusion criteria for the 
analysis were age at the onset of the disease > 40 years, duration 
of DM of < 5 years, pregnancy, and neoplastic diseases.
All the patients underwent a detailed physical examination (age, 
weight, height, BMI, age at which T1DM was diagnosed, and 
its duration). The form of diabetes treatment was established: 
continuous subcutaneous insulin infusion (CSII) or multiple daily 
subcutaneous injections (MDI). Using fasting venous blood tests 
(glycaemia, lipid profile, and levels of HbA1c, creatinine, and TSH), 
biochemical determinations of metabolic control were performed 
and its possible complications assessed. The albumin-to-creatinine 
ratio was checked using morning urine samples. Biochemical tests 
were performed at the main laboratory diagnostics department in 
the hospital, in accordance with standard procedures. In the lipid 
profile, total cholesterol, LDL, HDL, and triglycerides were tested. 
Non-HDL-cholesterol was calculated using the following formula: 
non-HDL-C = total cholesterol – HDL. Achievement of lipid level 
targets were analysed in our study by taking into consideration both 
LDL and non-HDL cholesterol levels for a complete evaluation. The 
diagnosis and evaluation of diabetic kidney disease was performed 
in accordance with the Kidney Disease Outcomes Quality Initiative 
(KDOQI), through the assessment of albumin excretion in urine 
and the eGFR according to the MDRD formula [9]. The diagnosis 
of Hashimoto thyroiditis was based on a combination of clinical 
features, the presence of serum antibodies against thyroid antigens, 
and the appearance on a thyroid sonogram. 
To assess the severity of the symptoms of CAN, recommended 
diagnostic methods were used, such as the Ewing test [10, 11], 
performed with ProSciCard apparatus (Mewicon CATEEM-Tec 
GmbH, Tab. I). Non-invasive functional tests were performed in 
the morning, on an empty stomach, in patients who had been 
fasting for a minimum of six hours. Patients did not drink alcohol 
or smoke in the 12 hours prior to the study. Medications that could 
affect autonomic functions (such as b-blockers, anticholinergics, 
antihistamines) were discontinued prior to testing, where possible. 
The set of tests carried out included the Valsalva test, a deep breath 
test, an orthostatic test, and the analysis of sinus rhythm variability. 
CAN was diagnosed when at least three tests were abnormal. 
the parasympathetic system (the variability of the heart 
rate during the Valsalva test, deep breathing, and after 
changing position to orthostatic) and the sympathetic 
system (variation of blood pressure both in an ortho-
static position and after physical exercise).
One of the elements of metabolic control for patients 
with DM is monitoring the lipid profile. In terms of lipid 
control, the DCCT study showed that cholesterol levels 
were similar to the control group without diabetes, as 
long as metabolic control was achieved [3]. A study 
has also been published showing a significantly higher 
(over 65% of the population) prevalence of lipid pro-
file disorders in children and adolescent patients with 
T1DM [8]. These studies and the higher risk of cardio-
vascular complications in T1DM patients indicate that 
such patients require an intensive approach to lipid 
treatment.
Considering the various results of reports on the 
significance of metabolic compensation in the preven-
tion of cardiovascular complications in DM patients, the 
present study evaluated metabolic control (glycaemic 
and lipid levels) obtained using two different kinds of 
insulin therapy (MDI and CSII) and the prevalence of 
CAN in T1DM patients without a positive history of 
ischaemic heart disease. 
Material and methods
This study is a retrospective analysis of a group of 93 adult patients 
(60 women, 33 men), selected from a total of 162 T1DM patients 
who underwent diagnostic tests for CAN, treated in a local clinical 
centre from 2011 to 2015. The study included people with T1DM 
Table I. Evaluation of autonomic cardiovascular function — Ewing’s test
Normal Borderline Abnormal
PNS Variation of HR
Valsalva test (Valsalva coefficient) ≥ 1.21 1.11–1.20 ≤ 1.10
Deep breathing (max/min HR; beats/min) ≥ 15 11–14 ≤ 10
Orthostasis coefficient 30:15;  
(R-R variability)
≥ 1.04 1.01–1.03 ≤ 1.00
SNS Variability of BP
Orthostasis (reduction in SBP, mm Hg) ≤ 10 11–29 ≥ 30
Exercise (increase in DBP, mm Hg) ≥ 16 11–15 ≤ 10
Valsalva coefficient The quotient of the maximum R-R interval of the ECG curve in phase 4 of the Valsalva trial (increase 
BP above the values determined before the test with subsequent bradycardia) to the minimal R-R 
interval in phase 2–3. (phase 2: lowering BP followed by its normalisation, accompanied by an 
acceleration of cardiac function, phase 3: increase in BP with cardiac acceleration) (RR max [4]/RR 
min [2–3]). Phase 1 of the Valsalva trial involves a transient increase in BP and a reduction in pulse 
rate as a result of increased blood flow to the peripheral circulation
Orthostasis coefficient 30:15 The quotient of the maximum RR interval of around 30 (usually 21–45) HB to the minimum RR 
interval of about 15 (usually 5–25) HB after upright positioning (RR max [21–45]/RR min [5–25])
PNS — parasympathetic nervous system; SNS — sympathetic nervous system; HB — heart beat; HR — heart rate; SBD — systolic blood pressure; DBP — diastolic 
blood pressure; BP — blood pressure
325
Endokrynologia Polska 2019; 70 (4)
O
R
IG
IN
A
L
 P
A
P
E
R
The results were subjected to statistical analysis using Student’s 
t-test or U-Mann-Whitney test and a one-factor and logistic regres-
sion analysis. The normality of distribution of continuous variables 
was tested using the Shapiro-Wilk test. Continuous variables with 
normal distribution were presented as the mean ± standard devia-
tion (SD); non-normal variables were reported as the median. For 
selected variables, multivariate regression analysis was performed 
using the following independent variables: age, duration of dia-
betes, glycaemia, HbA1c, presence of chronic kidney disease, BMI, 
LDL, HDL, TG, and non-HDL-C. A c2 test or Fisher’s test was used 
for qualitative data.
Descriptive statistics, including the mean and SD for continuous 
data, as well as frequency and proportions for qualitative data, were 
used to describe the characteristics of groups. Statistical significance 
was set at p < 0.05. The statistical analysis was conducted using R 
software (ver. 3.2.4).
Results
A total of 93 people qualified for the further analysis of 
this study: 60 women (62.5%) and 33 men (37.5%). The 
patients’ mean age at the time of the study was 31 years 
(18–66). The median duration of diabetes was 16 years; the 
median age of onset was 13 years. The occurrences of co-
morbidities and other chronic complications of DM were 
analysed. The presence of Hashimoto’s disease was found 
in 29.2% of the tested group, and its occurrence was not 
related to the duration of DM (p = 0.44). Kidney damage 
characterised by low creatinine clearance < 60 mL/min 
(stage ≥ 3 KDIGO) and/or albuminuria ≥ 30 mg/mmol [10] 
appeared in 24.8% of patients. The clinical characteristics 
of the whole tested group are shown in Table II.
Of the examined patients, 57 people (61%) were us-
ing MDI, and the rest (39%) were using CSII. The daily 
insulin dose (41 U vs. 45 U) in both analysed groups did 
not differ significantly. The mean duration of diabetes 
(13.8 ± 4.7 vs. 18.9 ± 10 years, p < 0.007) was lower 
in the group treated with CSII. At the same time, the 
mean age of patients in the group treated with CSII 
was lower compared to patients using MDI (27.6 ± 9.1 
vs. 40.6 ± 12.2 years, p < 0.001). The level of HbA1c in 
the CSII group was considerably lower compared to the 
MDI group (7.44 ± 1.67% vs. 8.55 ± 1.1%, p < 0.001).
In the examined group of patients, the lipid 
profile was assessed based on the 2016 ESC/EAS 
guidelines: a therapeutic target of LDL cholesterol 
levels of < 2.6 mmol/L for people under 40 years of 
age and < 1.8 mmol/L for older patients [13]. This 
criterion was met by 72% and 13% of the respective 
groups. The percentage of people who had achieved 
target non-HDL-C level was also assessed. In the 
group < 40 years of age 90.3% met the standards 
(non-HDL-C < 3.4 mmol/L), and in the group ≥ 40 years 
of age 29.2% of patients were within the reference range 
(non-HDL-C < 2.6 mmol/L). 
The analysis of individual lipidogram fractions 
showed a significantly higher triglyceride level in pa-
tients < 40 years of age:
 — with diagnosed CAN vs. without (p < 0.02, Tab. III);
 — treated with MDI vs. CSII (p < 0.002, Tab. IV). 
Of the T1DM patients studied, 41% (n = 38) pre-
sented with CAN. Upon evaluating the studied popula-
tion’s treatments of T1DM, it was found that CAN was 
notably more frequent in the subset of MDI patients 
compared with CSII (60.4% vs. 15.4%, p < 0.001, Fig. 1).
It was also shown that people who were diagnosed 
with CAN had a longer duration of T1DM than those 
who were not (22.1 ± 9.6 years vs. 15.2 ± 6.8 years, 
p < 0.001). Concurrently, HbA1c levels were substantially 
higher in patients with T1DM complicated by CAN 
compared to the group without CAN (8.62 ± 1.72% 
vs. 7.78 ± 1.39%, p < 0.01, Tab. IV). However, the level 
of diabetes control (HbA1c level) did not correlate with 
the duration of T1DM (p = 0.21). In multivariate analy-
sis significant parameters for the development of CAN 
were included.
When considering treatment method, age, duration 
of DM, metabolic control (HbA1c and HDL level), and 
the presence of kidney failure, multivariate regression 
analysis of the occurrence of CAN confirmed a sig-
nificant relationship between CAN and the following 
factors:
 — duration of DM (p = 0.02); 
 — HDL level (p = 0.04);
 — diagnosed kidney failure (p = 0.01);
but no significant relationship with the following:
 — treatment with CSII (p = 0.99);
 — age (p = 0.57);
 — HbA1c level (p = 0.18, Tab. V).
Table II. Clinical characteristics of study participants 
with type 1 diabetes mellitus (T1DM) (n = 93) 
Parameter Prevalence
Sex (F/M) % 64.5/35.5
Age (years) 18–66 (median 31)
Duration of diabetes (years) 5–44 (median 16)
Weight [kg] 44–100 (mean 67.3 ± 12)
Height [cm] 152–187 (median 167)
BMI [kg/m2] 14.8–33.6 (median 23.2)
HbA1c (%) 5.9–12.9 (median 7.8)
Hashimoto disease prevalence 29.2 (%)
Ckr < 60 mL/min 6.50 (%)
Albuminuria ≥ 30 mg/d 21.50 (%)
BMI — body mass index; HbA1c — glycated hemoglobin; Ckr — creatinine 
clearance
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Discussion
To our knowledge, this is the first study of a group of 
patients with T1DM, their lipid targets, and the occur-
rence of CAN, which considers metabolic control and 
the method of insulin therapy used. A few years ago, 
a draft register of diabetic patients included patients 
with T1DM but focused mostly on the quality of dia-
betes care in all patients [12]. Nevertheless, the authors 
emphasised the lack of metabolic control optimisation, 
including the level of lipids, in patients with various 
types of diabetes (T1DM, T2DM, GDM).
It is believed that CSII enables better physiological 
control over insulin dosage. This should translate into 
an improvement in metabolic control in T1DM patients, 
such as a better glycaemic level or lipid profile [13]. In the 
presented analysis, the level of HbA1c was significantly 
lower in the CSII group compared to the group treated 
using MDI. This observation is consistent with reports 
from other centres in which a significant reduction in 
level of HbA1c was demonstrated just a few months after 
Table IV. Characteristics of metabolic control in patients with type 1 diabetes mellitus (T1DM) (n = 93) treated with continuous 
subcutaneous insulin infusion (CSII) (n = 36) and multiple daily subcutaneous injections (MDI) (n = 57)
Parameter CSII MDI Significance
Age (years) 25.94 ± 5.99 38.4 ± 11.32 p < 0.001
HbA1c (%) 7.44 ± 1.14 8.55 ± 1.67 p < 0.001
Lipidogram [mmol/L]
Total cholesterol 4.02 ± 0.6 4.45 ± 0.89 p < 0.05
LDL-C 2.07 ± 0.53 2.57 ± 0.79 p = 0.57
Non-HDL-C 1.28 ± 1.32 2.82 ± 1.06 p < 0.001
TG
< 40 years old
≥ 40 years old
0.70 ± 0.19
1 [one person]
1.25 ± 0.82
1.43 ± 1.14
p < 0.002
not applicable
HbA1c — glycated hemoglobin; LDL — low density lipoprotein; HDL — high density lipoprotein; TG — triglycerides
Table III. Characteristics of type 1 diabetes mellitus (T1DM) patients regarding the occurrence of cardiovascular neuropathy (n = 93)
Parameter CAN (+) CAN (–) Significance
DM duration (years) 22.1 ± 9.60 15.24 ± 6.84 p < 0.001
HbA1c (%) 8.62 ± 1.72 7.78 ± 1.39 p < 0.01
Lipidogram [mmol/L]
Total cholesterol 4.22 ± 0.85 4.43 ± 0.83 p = 0.33
LDL-C 2.37 ± 0.76 2.47 ± 0.76 p = 0.57
Non-HDL-C 2.54 ± 1.13 2.00 ± 1.50 p = 0.15
TG
< 40 y.o.
≥ 40 y.o.
1.27 ± 0.91
1.40 ± 1.14
0.86 ± 0.44
1.43 ± 1.14
p < 0.02
p = 0.82
CAN (+) — T1DM patients who developed cardiovascular autonomic neuropathy; CAN (–) — T1DM patients without cardiovascular autonomic neuropathy;  
DM — diabetes mellitus; HbA1c — glycated hemoglobin; LDL — low density lipoprotein; TG — triglycerides
Figure 1. Prevalence of cardiovascular autonomic neuropathy in 
a group of patients with type 1 diabetes mellitus (T1DM) treated 
with multiple daily subcutaneous injections (MDI) (n = 57) vs. 
patient treated with continuous subcutaneous insulin infusion 
(CSII) (n = 36) (p < 0.001)
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the implementation of pump therapy [13, 14]. At the 
same time, regardless of the T1DM treatment method, 
we observed significantly worse metabolic control in 
patients with CAN in terms of HBA1c level. A similar 
relationship was found in the DCCT study, in which it 
was shown that more intensive treatment of diabetes 
and better metabolic control had a preventive effect on 
the development of complications [15].
In the present study, there was a notably lower 
proportion of patients with CAN in the group treated 
with CSII. This significant difference is due to better 
glycaemic control and the shorter duration of the 
disease, and was not directly related to the therapy 
method itself.  It is worth noting that, according to 
the guidelines of Diabetes Poland [16] and ADA [17], 
the first assessment for neuropathy in a patient with 
T1DM should be conducted five years after the onset 
of diabetes. However, Pfeifer et al. showed that people 
with T1DM, even after the first two years of the disease, 
may present early stages of CAN expressed by a reduc-
tion in the RR interval variation during b-adrenergic 
blockade [18].
Until now, the pathogenesis of diabetic neuropathy 
has not been clearly established. Two main theories are 
recognised in the pathogenesis of this disease: metabolic 
and ischaemic [19]. Our observations refer to the first 
of them, according to which the excess of glucose is 
transformed by aldose reductase into sorbitol and then 
into fructose. The accumulation of these compounds 
in neurons due to osmotic effects, oxidative stress, and 
the generation of free radicals causes a decrease in the 
biosynthesis of metabolites necessary for the function-
ing of the nerve cell and leads to apoptosis [20]. 
A rise in the frequency of CAN increases mortality 
caused by cardiac arrhythmias, especially of ventricular 
origin, and episodes of silent myocardial ischaemia 
[21].  In addition, diabetes is a known, independent 
risk factor for coronary heart disease, predisposing to 
severe and disseminated atherosclerotic lesions in ves-
sels [22]. The whole picture argues for the necessity of 
permanent supervision of cardiac patients with T1DM, 
in whom, regardless of the method of treatment, there 
is a significant percentage of overt, chronic metabolic 
complications significantly increasing the risk of death.
In this study, when analysing lipidogram results, 
unsatisfactory lipid control was found. LDL-cholesterol 
level is one of the most important, independent fac-
tors promoting atherosclerosis, but it is still found not 
to be properly treated. Although a high percentage 
of patients in the < 40 years age group was within 
therapeutic targets, as much as 87% of the population 
of older patients (> 40 years old) had an abnormal LDL 
level. Furthermore, patients with a chronic disease such 
as diabetes, who are in constant contact with a family 
doctor at least to obtain prescriptions for insulin, are not 
adequately supervised for lipid disturbances. Non-HDL 
cholesterol was found to be elevated in over 70% of 
patients > 40 years old, but its role in T1DM has not 
been established yet. 
Previous studies on the lipid profile analysis of pa-
tients with DM concerned mainly type 2 DM, where 
the importance of abnormalities in the lipid profile in 
the aetiopathogenesis of cardiovascular diseases has 
been confirmed [23]. Published studies on lipid profile 
assessments in patients with T1DM in relation to a con-
trol group without diabetes showed significantly lower 
levels of analysed parameters in patients with T1DM 
[24]. New data are expected soon from the completed 
Adolescent type 1 Diabetes cardio-renal Intervention 
Trial (AdDIT) to provide information about potential 
renal and cardiovascular protective effects of ACEI 
and statins in high-risk adolescents [25]. For now, the 
assessment of risk of cardiovascular complications is 
similar for both types of diabetes. Collins provided 
direct evidence that statin therapy is beneficial for 
diabetic patients even if they do not have clear signs 
of coronary disease or high cholesterol concentrations, 
which suggests that cholesterol-lowering drugs should 
be considered as routine therapy for all diabetic patients 
irrespective of their initial cholesterol level, to prevent 
Table V. The association between different clinical variables and cardiovascular autonomic neuropathy in diabetes type 1 
patients, the multivariate logistic regression-derived odds ratios (OR) [and 95% confidence intervals (CI)], statistical significance 
p < 0.05
Parameter OR 95% CI p
CSII usage (YES) 0.99 0.21–4.61 0.99
Age (years) 0.98 0.92–1.05 0.57
Diabetes duration (years) 1.11 1.02–1.23 0.02
HbA1c (%) 1.33 0.88–2.06 0.18
HDL [mmol/L] 0,22 0.04–0.81 0.04
Presence of kidney failure (YES) 7.85 1.86–43.24 0.01
CSII — continuous subcutaneous insulin infusion; HbA1c — glycated hemoglobin; HDL — high density lipoprotein
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the development of angioneuropathy [26]. In addition, 
recent observations regarding an abnormal lipid profile 
in children and adolescents with T1DM emphasise the 
important role of monitoring this parameter in medical 
care for all patients with T1DM [8]. We showed a statis-
tically significant relationship between the use of CSII 
and lower triglyceride levels, which is probably related 
to decreased lipolysis in better controlled DM patients 
[27]. Our results draw attention to this problem for the 
first time and indicate the need for more intensive moni-
toring and treatment of hyperlipidaemia, especially 
LDL, in adult patients mainly over the age of 40 years.
The presented study is a retrospective observation. 
The relatively small group of participants weakens the 
power of the work. However, it should be remembered 
that these are patients with T1DM, who constitute 
a homogeneous group from the southern region of 
Poland, which reduces the impact of disturbing envi-
ronmental factors. In accordance with earlier reports, 
in our examined group better metabolic control was 
achieved with CSII, which confirms the high value of 
new technologies in T1DM treatment. However, the 
lack of a relationship between CAN and treatment 
method in multivariate regression analysis might be 
due to the younger age range and the shorter dura-
tion of the disease in patients treated with CSII. This 
results from economic conditions and reflects the real 
profile of the treatment method for patients in our so-
ciety. Since 2009, the National Health Fund (NFZ) has 
financed the purchase of insulin pumps for children 
and adolescents up to 18 years of age, and since 2011 
this limit has been raised to 26 years of age. The shorter 
average duration of treatment using personal pumps 
vs. insulin pens is due to the fact that these devices have 
been available in clinics for a much shorter time than 
therapy with pens.
Conclusions
In conclusion one innovative point in our study is that 
it draws attention to the need for comprehensive and 
accurate monitoring of patients with T1DM in terms of 
CAN risk, due to the very high prevalence of cardio-
vascular complications in such patients. It confirms the 
beneficial effect of glycaemic control, and, at the same 
time, draws attention to the non-optimised treatment of 
lipids, which intensifies the mechanisms for the devel-
opment of angioneuropathy. Our results also highlight 
the need for clinicians to monitor overall metabolic 
control in patients with T1DM, even those who have 
not yet developed the chronic complications of diabetes 
but have reached the age of about 40 years. Proper and 
comprehensive care of patients with T1DM requires, in 
addition to measuring the level of glycaemia, regular 
(minimum once a year) biochemical monitoring of other 
parameters of metabolic control.
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